Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab vs Active Surveillance After Nephrectomy in Non-Clear Cell Renal-Cell Carcinoma
NCT07689240Phase 3Not yet recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2027
- Primary completion
- Jan 2032
01
Overview
A Phase 3 trial of pembrolizumab in non-clear cell renal cell carcinoma (nccRCC), sponsored by National Cancer Institute. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NCT07689240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07689240.